| Ytd | 81.53% | |
| 1y | -6.86% |
| Open | 5.57 | Prev Close | 5.58 | Low | 5.55 | High | 5.84 | Mkt Cap | 232.36M |
| Vol | 312.22K | Avg Vol | 3.93M | EPS | 2.52 | P/E | 2.21 | Forward P/E | -0.28 |
| Beta | 1.55 | Short Ratio | 4.16 | Inst. Own | 37.10% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 3.54 | 200-d Avg | 3.68 | 1yr Est | 8.00 |
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in i
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer stud
Agenus Inc. (AGEN) stock experiences profit-taking on Tuesday after a 111% surge. Discover the lates
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average
U.S. stock futures were mixed on Tuesday, as the Nasdaq 100 index advanced, while the Dow Jones and
ORCL, VEEE, AGEN, MU, SNDK were among the stocks seen trending on Monday, July 13, 2026.
Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session
US stocks dip, Nasdaq falls 1%. Dow down 0.34%. Energy shares up 2.1%, tech down 1.2%. Micron Tech d
HC Wainwright & Co. analyst Emily Bodnar maintains Agenus (NASDAQ:AGEN) with a Buy and raises
Agenus ($AGEN) stock rockets over 111% following stellar 3-year colorectal cancer data and a $340M f
Agenus Inc. (NASDAQ:AGEN) stock surged over 100% in intraday trading on Monday after the immuno-onco
Agenus stock surged 100%, after the biotech secured up to $340 million in fresh capital, extended it
Agenus NASDAQ: AGEN said it is shifting its development focus and financial resources toward a Phase
US stocks mixed, Dow up 100 points. Energy up 2.1%, tech down 1.1%. LogProstyle Inc shares rise on e
Agenus (Agenus Inc (NASDAQ:AGEN)) shares jumped about 100% on Monday after the biotechnology company
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke
QTTB: 82% | Q32 Bio shares are trading higher after the company it will report 36-week topline resul
VivoPower PLC (NASDAQ:VIVO, FRA:51J)’s pivot toward acquiring and developing power-secured land and
Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology innovation, today announced that it has enter
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc
Fully enrolled 123-patient Phase 1b cohort demonstrated 21.2-month median overall survival, 33% thre
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BAL--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-onc
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha
Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus
LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio
Agenus NASDAQ: AGEN told shareholders at its 2026 virtual annual meeting that it remains focused on
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launc
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, diluti
Agenus bets on BOT+BAL in MSS mCRC, and the phase III BATTMAN trial determines whether early surviva
LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (“Agenus”) (NASDAQ: AGEN), a leader i
Iovance's commercial momentum and expanding Amtagvi pipeline make it appear better positioned than A
First presentation of BOT+BAL melanoma data in heavily pretreated patients whose disease had resiste
Noetik's TARIO-2 platform analyzed routine pretreatment H&E images from 113 BOT+BAL-treated
Published prospective cohort showed durable responses and manageable safety in patients with HCC fol
First study combining botensilimab (BOT) and balstilimab (BAL) with agenT-797 in gastroesophageal ca
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
On Tuesday, 647 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn
During Monday's trading, 1214 companies set new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.